OTCMKTS:RZLTD

Rezolute (RZLTD) Stock Price, News & Analysis

$2.66
+0.06 (+2.31%)
(As of 04/26/2024 ET)
Today's Range
$2.54
$2.71
50-Day Range
$1.35
$3.54
52-Week Range
$16.00
$24.05
Volume
203,470 shs
Average Volume
4,788 shs
Market Capitalization
$22.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

RZLTD Stock Price History

RZLTD Stock News Headlines

Rezolute (RZLT) Earnings Dates & Reports
Xilio Development Inc (XLO)
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Systems Ltd.
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Rezolute (RZLT) Gets a Buy from H.C. Wainwright
See More Headlines
Receive RZLTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:RZLTD
CIK
N/A
Fax
N/A
Employees
23
Year Founded
N/A

Profitability

Net Income
$-20,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$22.39 million
Optionable
Not Optionable
Beta
4.63
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Nevan Charles Elam (Age 53)
    CEO & Director
    Comp: $869.45k
  • Dr. Keith A. Vendola M.B.A. (Age 48)
    M.D., MBA, Chief Financial Officer
    Comp: $422.76k
  • Dr. Sankaram Mantripragada (Age 60)
    Chief Scientific Officer
    Comp: $620.76k
  • Mr. Michael R. Deperro
    Head of Operations
  • Dr. Brian Roberts
    Head of Clinical Devel.
  • Ms. Paula Opal
    Head of Regulatory
  • Dr. Sharon Xueyan Wang
    Head of Preclinical Devel.

RZLTD Stock Analysis - Frequently Asked Questions

How have RZLTD shares performed in 2024?

Rezolute's stock was trading at $0.9925 at the beginning of 2024. Since then, RZLTD shares have increased by 168.0% and is now trading at $2.66.
View the best growth stocks for 2024 here
.

How do I buy shares of Rezolute?

Shares of RZLTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:RZLTD) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners